Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 27, Number 11—November 2021
Dispatch

Effectiveness of BNT162b2 Vaccine in Adolescents during Outbreak of SARS-CoV-2 Delta Variant Infection, Israel, 2021

Aharona Glatman-FreedmanComments to Author , Yael Hershkovitz, Zalman Kaufman, Rita Dichtiar, Lital Keinan-Boker, and Michal Bromberg
Author affiliations: The Israel Center for Disease Control, Ramat Gan, Israel (A. Glatman-Freedman, Y. Hershkovitz, Z. Kaufman, R. Dichtiar, L. Keinan-Boker, M. Bromberg); Tel Aviv University, Tel Aviv, Israel (A. Glatman-Freedman, M. Bromberg); Haifa University, Haifa, Israel (L. Keinan-Boker)

Main Article

Figure 2

Vaccine effectiveness against severe acute respiratory syndrome coronavirus 2 infection in adolescents 12–15 years of age, by time after second dose of BNT162b2 vaccine (Pfizer-BioNTech, https://www.pfizer.com), Israel, 2021. Error bars indicate 95% CIs.

Figure 2. Vaccine effectiveness against severe acute respiratory syndrome coronavirus 2 infection in adolescents 12–15 years of age, by time after second dose of BNT162b2 vaccine (Pfizer-BioNTech, https://www.pfizer.com), Israel, 2021. Error bars indicate 95% CIs.

Main Article

Page created: September 23, 2021
Page updated: October 19, 2021
Page reviewed: October 19, 2021
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external